Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Zimmer, Lisa; Goldinger, Simone M; Hofmann, Lars; Loquai, Carmen; Ugurel, Selma; Thomas, Ioannis; Schmidgen, Maria I; Gutzmer, Ralf; Utikal, Jochen S; Göppner, Daniela; Hassel, Jessica C; Meier, Friedegund; Tietze, Julia K; Forschner, Andrea; Weishaupt, Carsten; Leverkus, Martin; Wahl, Renate; Dietrich, Ursula; Garbe, Claus; Kirchberger, Michael C; Eigentler, Thomas; Berking, Carola; Gesierich, Anja; Krackhardt, Angela M; Schadendorf, Dirk; Schuler, Gerold; Dummer, Reinhard; Heinzerling, Lucie M (2016). Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 60:210-225.

Heppt, Markus V; Reinholz, Markus; Tietze, Julia K; Kerl, Katrin; French, Lars E; Berking, Carola; Kamarashev, Jivko (2015). Clinicopathologic features of primary cutaneous melanoma: a single centre analysis of a Swiss regional population. European Journal of Dermatology, 25(2):127-132.

Van Allen, Eliezer M; Wagle, Nikhil; Sucker, Antje; Treacy, Daniel J; Johannessen, Cory M; Goetz, Eva M; Place, Chelsea S; Taylor-Weiner, Amaro; Whittaker, Steven; Kryukov, Gregory V; Hodis, Eran; Rosenberg, Mara; McKenna, Aaron; Cibulskis, Kristian; Farlow, Deborah; Zimmer, Lisa; Hillen, Uwe; Gutzmer, Ralf; Goldinger, Simone M; Ugurel, Selma; Gogas, Helen J; Egberts, Friederike; Berking, Carola; Trefzer, Uwe; Loquai, Carmen; Weide, Benjamin; Hassel, Jessica C; Gabriel, Stacey B; Carter, Scott L; Getz, Gad; Garraway, Levi A; Schadendorf, Dirk (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery, 4(1):94-109.

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, 14(3):249-256.

Voskens, Caroline J; Goldinger, Simone M; Loquai, Carmen; Robert, Caroline; Kaehler, Katharina C; Berking, Carola; Bergmann, Tanja; Bockmeyer, Clemens L; Eigentler, Thomas; Fluck, Michael; Garbe, Claus; Gutzmer, Ralf; Grabbe, Stephan; Hauschild, Axel; Hein, Rüdiger; Hundorfean, Gheorghe; Justich, Armin; Keller, Ullrich; Klein, Christina; Mateus, Christine; Mohr, Peter; Paetzold, Sylvie; Satzger, Imke; Schadendorf, Dirk; Schlaeppi, Marc; Schuler, Gerold; Schuler-Thurner, Beatrice; Trefzer, Uwe; Ulrich, Jens; Vaubel, Julia; von Moos, Roger; Weder, Patrik; Wilhelm, Tabea; Göppner, Daniela; Dummer, Reinhard; Heinzerling, Lucie M (2013). The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE, 8(1):e53745.

This list was generated on Tue Nov 21 21:32:20 2017 CET.